Skyelarke Announces New Enhancements to Patient Payment Platform, SkyePay
Skyelarke has announced new additions to SkyePay, a patient payment technology.
With the launch of faster payments via bank transfer, virtual cards, and PayPal/Venmo integration, on top of the physical card option, SkyePay is now providing patients with more options around how they receive their expense or stipend payments related to clinical trial participation.
In addition to increased patient payment choice, SkyePay has also developed an API framework, soon to be released, which will allow IRT, EDC, or ePRO integration.
Key benefits of the SkyePay platform include:
- For patients: automated and fast payments, multiple payment methods (bank transfer, card, and virtual), and reduced financial burden.
- For sites: no training required, ability to make fast payments, integrated receipt management, and sponsor/CRO approval process.
- For sponsors/CROs: transaction reporting for reconciliation purposes, fast approval processes, and privacy by design with data stored depending on where the study is.
Reference
Skyelarke furthers its mission to break down barriers to clinical trial participation, with new SkyePay enhancements. (2023, July 11). Cision PR Newswire.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
February 3rd 2025A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.
